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Abstract
Background: MicroRNA-21 is up-regulated in a variety of cancers like, breast, colorectal, lung, head and neck etc. However,
the regulation of miR-21 in renal cell carcinoma (RCC) has not yet been studied systematically.
Methods and Results: We measured miR-21 levels in 54 pairs of kidney cancers and their normal matched tissues by real-
time PCR. The expression level of miR-21 was correlated with 5 year survival and the pathological stage. Functional studies
were done after inhibiting miR-21 in RCC cell lines. We studied in vitro and in vivo effects of the chemo preventive agent
genistein on miR-21 expression. In 48 cases (90%), miR-21 was increased. All patients with low miR-21 expression survived 5
years, while with high miR-21 expression, only 50% survived. Higher expression of miR-21 is associated with an increase in
the stage of renal cancer. Functional studies after inhibiting miRNA-21 in RCC cell lines show cell cycle arrest, induction of
apoptosis and reduced invasive and migratory capabilities. Western blot analysis showed an increase in the expression of
p21 and p38 MAP kinase genes and a reduction in cyclin E2. Genistein inhibited the expression of miR-21 in A-498 cells and
in the tumors formed after injecting genistein treated A-498 cells in nude mice besides inhibiting tumor formation.
Conclusions: The current study shows a clear correlation between miR-21 expression and clinical characteristics of renal
cancer. Thus we believe that miR-21 can be used as a tumor marker and its inhibition may prove to be useful in controlling
cancers with up-regulated miR-21.
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Introduction
MicroRNAs are small non-coding RNAs that play important
roles in numerous cellular processes including development,
proliferation, and apoptosis [1]. Since miRNAs are involved in
critical cellular processes, recent studies have shown that they are
also involved in the pathogenesis of various diseases including those
ofthekidney. CharacteristicmiRNAsignatures forseveral epithelial
cancers, including breast, lung, pancreatic, gastric and renal
cancers, have been reported [2,3,4,5]. Histological evidence shows
that there are several variants of malignant renal cell carcinoma, viz.
clear cell, papillary, chromophobe and collecting duct carcinomas
[6,7,8,9]. Several studies have shown differential expression of
miRNA in these variants of renal cell carcinoma [10,11,12].
MicroRNA-21 isup-regulated ina variety ofcancers,such asbreast,
colorectal, lung, head and neck, etc. However, the regulation and
functional role of miR-21 in kidney cancer has not yet been
systematically studied. In this study we measured miR-21 levels in
54 pairs of human kidney cancers and their normal matched tissues
by real-time PCR. The expression level of miR-21 was correlated
with 5 year survival and stage of the patients. In order to determine
the role of miR-21 in renal cell carcinoma (RCC) functional assays
such as cell cycle, apoptosis, invasion, and migration, were done
after knocking down miR-21 expression in A-498 cells. Software
analysis and PCR array analysis showed an increase in the
expression of p21 and p38 MAP kinases after the inhibition of
miR-21 and decreased expression of cyclins and cyclin dependent
kinases. These results were validated by Western analysis.
Furthermore, we also assessed the effect of a dietary chemopreven-
tion agent, genistein (a soy product), on the expression of miR-21 in
mice tumors. Genistein reduced the expression of miR-21 in mice
injected with genistein treated cells as compared to vehicle controls.
This is the first study which shows the correlation of miR-21
expression with clinical parameters and it’s functional role in RCC.
In conclusion,up-regulatedmiR-21inkidney cancermaybe a good
tumor marker for kidney cancer diagnosis.
Results
miR-21 is up regulated in renal carcinoma tissue samples
and renal cancer cell lines
To understand the clinical relevance of miR-21 in kidney
cancer we measured miR-21 levels in 54 pairs of kidney cancers
and their matched normal tissues by real-time PCR. In 48 cases
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was greater than 1.2). Expression of miR-21 was also measured in
renal cancer cell lines, A-498, Caki-1, Caki-2 and normal HK-2
cells. miR-21 expression in A-498 cells was about 7.36 that of
HK-2 cells while that of Caki-1 was 1.66, and Caki-2, 36.
Correlation of miR-21 expression with stage and survival
in renal cancer
The expression level of miR-21 correlated with 5 year survival
and stage of the patients. For patients with low miR-21 expression
(Figure S1), all survived 5 years after surgery, while for those with
high miR-21 expression (Figure S2), only 50% survived (Figure 1).
The survival curve was based on the number of patients (36) for
which we had survival information out of a total of 54 patients. In
groups of patients having low miR-21 expression (T/N,1.2), high
expression (T/N=1.2–10) and very high expression (T/N.10),
the percent of those in early stage (Stage I) decreased by 80%,
51.5% and 37.5%, respectively. This implies that increased
expression of miR-21 correlates with an increased stage of renal
cancer. This information was based on the number of patients for
whom we had the stage information (46 out of 54 patients). No
correlation between tumor grade and miRNA-21 levels was
observed.
Expression of miR-21 in different forms of renal cell
cancer
The expression of miR-21 was graded as either low (T/N,1.2),
high (T/N=1.2–10) and very high (T/N.10). The different
forms of cancers in which the expression of miR-21 was analyzed
were clear cell carcinoma, papillary carcinoma and tubular
carcinoma. Out of a total of 54 samples, 45 samples were clear
cell carcinoma, 8 were papillary and 1 was tubular carcinoma. In
both clear cell (71.1%) and papillary carcinoma (75%) the majority
of samples had high expression of miR-21 (T/N=1.2–10). 17.7%
of clear cell carcinoma had very high expression. The single
tubular renal cell carcinoma sample had very high miR-21
expression.
Functional role of miR-21 in A-498 cells
To elucidate the functional role of miR-21 in renal cancer we
inhibited the expression of miR-21 in A-498 renal cancer cells with
a commercially available miR-21 inhibitor. Anti-miR-Negative
control #1 was used as the standard negative control for these
experiments. The miR-21 level was reduced by more than 99%, as
compared to the negative control (Figure S3). In the case of anti-
miR-21 transfection into Caki-2 cells the same level of reduction of
miR-21 expression was observed (Figure S4).
Effect on A-498 cell cycle and apoptosis. The effects of
miR-21 inhibition on the cell cycle and apoptosis were analyzed by
flow cytometry. The cell cycle showed a significant increase (9.1%)
in the G0/G1 phase, with a concomitant reduction (6.8%) in the
G2/M phase, indicating that the reduction of miR-21 expression
in A-498 cells inhibited the cell growth and caused G0/G1 arrest
(Figure 2a). Apoptosis assay using flow cytometry showed a
marginal increase in the number of total apoptotic cells (early
apoptotic plus apoptotic) (5.17%) in the miR-21 anti-miRNA
inhibitor transfected cells as compared to the negative control
(1.79%) and mock (2.49%) (Figure 2b). In case of Caki-2 cells
inhibition of miR-21 resulted in a significant increase in apoptosis
with no change in cell cycle (data not shown).
Figure 1. Correlation of miR-21 expression with 5 year survival of renal cell carcinoma patients.
doi:10.1371/journal.pone.0031060.g001
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determine whether miR-21 affects renal cancer cell migration and
invasion a cytoselect 24-well cell migration and invasion kit was
used. A-498 cells were transfected with anti-miR-21 inhibitor and
anti-miR-Negative control. Both A-498 cell invasion and
migration were decreased as compared to negative control. Less
absorbance was observed at 560 nm with anti-miR-21 transfected
cells than the negative control in both the invasion and migration
assays (Figures 3a and 3b). Inhibition of miR-21 expression had a
more pronounced effect on invasion as compared to migration,
(reduction of 50% vs 25%). Similar effects were observed in the
case of Caki-2 cells in both invasion and migration assays (data not
shown).
miR-21 increases the expression of cyclin dependent
kinase inhibitor CDKN1A (p21). To see the effect of miR-
21 expression on different genes involved in the cell cycle and
apoptosis we used PCR arrays. Since we saw a significant effect on
the cell cycle by inhibition of miR-21 in A-498 cells, we first
Figure 2. Effect on cell cycle and apoptosis after knocking down miR-21 in A-498 cells. (a) Effect on cell cycle: Flow cytometry analysis of
the cell cycle showed a significant increase in G0/G1 phase (9.1%), with a concomitant reduction in the G2/M phase (6.8%), indicating that the forced
reduction of miR-21 expression in A-498 cells could inhibit the cell growth and cause G0/G1 arrest (p value 0.010). (b) Effect on apoptosis: Apoptosis
assay showed a marginal increase in the number of total apoptotic cells (5.17%) in the miR-21 anti-miRNA inhibitor transfected cells as compared to
the negative control (1.79%) and mock (2.49%) (p value 0.017).
doi:10.1371/journal.pone.0031060.g002
Figure 3. Effect on cell invasion and migration on A-498 cells after miR-21 inhibition. (a) Effect on cell invasion: Invasive properties of A-
498 cells were decreased after the inhibition of miR-21 as compared to the negative control, Stained A-498 cells (Magnification-406); Absorbance at
560 nm (p value 0.026). (b) Effect on cell migration: Migratory properties of A-498 cells were also decreased after the inhibition of miR-21 as
compared to the negative control, Stained A-498 cells (Magnification-406); Absorbance at 560 nm (p value 0.016).
doi:10.1371/journal.pone.0031060.g003
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based PCR arrays showed changes in the expression of a number
of genes. One of the genes up regulated in the PCR array after the
inhibition of miR-21 was the cyclin dependent kinase inhibitor,
CDKN1A also known as Cip1 or p21. Other PCR arrays showed
a change in the expression of the gene p38 MAP kinase.
Subsequently, we verified this result using MAP kinase based
PCR arrays and obtained the same result (data not shown). Both
results were validated by Western blotting (Figure 4). Western
blotting experiments clearly show up regulation of both p21 and
p38 MAP kinase genes with miR-21 inhibition as compared to the
negative control. We also checked the expression of other genes
related to the cell cycle and apoptosis and found downregulation of
cyclin E2. We also looked at mRNA expression of cyclin
dependent kinases, CDK2, CDK4, CDKE1 and CDKE2 and
found their expression to be significantly reduced after inhibition
of miR-21 (data not shown). In Western blot experiments we
checked CDK4, E1 and E2 as CDK2 is already known to be
affected by p21 gene [13,14]. We observed a change in protein
expression for only CDKE2.
In vitro and In vivo effects of genistein on renal cancer
cells
Genistein reduces the expression of miR-21 in mouse
tumors. As mentioned earlier we checked the effect of a
chemoprevention agent, genistein (a soy product), on the
expression of miR-21 in nude mouse tumors. Firstly A-498 renal
cancer cells were treated with 25 mM genistein for 4 days and
subsequent to RNA extraction miR-21 expression was checked.
The expression was observed to be reduced by 30% in genistein
treated cells as compared to untreated ones (Figure 5a). To see the
effect of genistein treatment on mice tumors and miR-21
expression A-498 cells were again treated with genistein (25 mM)
and after 96 hours of treatment were injected subcutaneously into
nude mice. Two sets of three mice each were used. In the DMSO
control tumors the three mice developed significantly large sized
tumors, approximately 800 mm
3 in volume (Figure 5b, left panel),
whereas with the genistein treated cells a small size tumor was
observed in one out of three mice, approximately 25 mm
3 in
volume (Figure 5b right panel,). In the other two mice one of them
had a very small tumor at the site of the injection (Figure 5b right
panel) while the third mouse had no tumor. After the formation of
palpable tumors with control cells, we excised the tumors and
measured the expression of miR-21 subsequent to the tumor
homogenization with Qiazol and RNA extraction. The expression
of miR-21 was found to be reduced by ,40% in genistein treated
samples as compared to untreated ones (data not shown).
Discussion
In the present study we provide evidence that up regulation of
miR-21 in renal cell carcinoma is related to lower survival of
kidney cancer patients. The expression of miR-21 in both kidney
cancer cell lines and human kidney cancer tissue samples was
found to be higher as compared to normal, which is in accordance
with previous studies on renal cell carcinoma and also other types
of cancer [15]. Our study shows for the first time that patients with
a higher expression of miR-21 in renal cancer have a lower
probability of survival. Also, lower expression of miR-21 leads to a
higher survival rate. We also correlated the expression of miR-21
with the stage of the cancer for those patients that we had
complete information regarding the stage (34/39). Our analysis
showed that very high expression of miR-21 in patient samples led
to an increase in stage of the disease. To elucidate the importance
of miR-21 in renal cell carcinoma functional assays were
performed. Cell viability assays showed an anti proliferative effect
on A-498 cells after the inhibition of miR-21. The most significant
change was observed in the cell cycle where the G0/G1 phase was
increased dramatically (9.1%) with a concomitant reduction in the
G2/M phase (6.8%). This led us to search for potential cell cycle
genes affected by inhibition of miR-21 in A-498 cells. Cell cycle
PCR array experiments showed that cDKN1A (p21) was up
regulated after inhibition of miR-21 in A-498 cells. Previous
studies using microarrays suggest that p21 expression positively
correlates with the suppression of genes that are important for cell
cycle progression [16]. p21 responds to a variety of stimuli that
promotes growth-inhibitory activities depending on its ability to
inhibit the activity of cyclin-dependent kinase, CDK2. Numerous
studies have reported that the p21 gene has additional roles in cell
cycle regulation which are independent of CDK2. Some examples
are its association with the transcription factor E2F1 and the
suppression of its transcriptional activity [17]. Furthermore, p21
also suppresses transcription factors STAT3 [18] and MYC [19].
In addition p21 also promotes cell cycle inhibition through the
mediation of p53-dependent repression of genes such as CDC25C,
CDC2, CCNB1 and BIRC5 also known as survivin [20,21,22].
Although p21 suppresses genes involved in cell cycle progression it
also inhibits apoptosis [23]. When cells face genotoxic insults or
microtubule-destabilizing agents, p21 protects them from apopto-
sis as an active cell cycle is required to sense these agents and
trigger apoptosis. This may account for the not so dramatic
increase in the number of cells undergoing apoptosis after the
inhibition of miR-21 in A-498 cells as compared to changes in cell
cycle progression Figure 2b. However, the effect of p21 is
counteracted by several mechanisms which involves switching
from cell cycle arrest to apoptosis by the selective transcriptional
repression of p21, the selective activation of pro-apoptotic genes or
defects in p21 expression downstream of p53 [24,25,26]. In certain
cases p21 also promotes apoptosis through both p53-dependent
and independent mechanisms under cellular stress but the
mechanism of action is still unknown [27]. Thus we tried to see
if p21 was a direct target of miR-21 using the 39 luciferase assay
but we could not find a direct interaction. Thus we checked the
Figure 4. Western analysis after the knock down of miR-21 in
A-498 cells. Expression of p21, p38MAP kinase and cyclin E2 after the
inhibition of miR-21 in A-498 cells, as compared to negative control.
GAPDH was used as a normalizing control. p21 and p38 MAP kinase
were up regulated, whereas cyclin E2 expression was found to be down
regulated.
doi:10.1371/journal.pone.0031060.g004
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and E2 and could find a difference in only cyclinE2 (Figure 4).
Genistein, one of the principal soy isoflavones, has a wide array
of chemopreventive actions. The anticancer effects of genistein
have been ascribed to several signalling pathways and mechanisms
that affect cell cycle arrest, apoptosis, invasion, metastasis and
angiogenesis, attributes that could potentially prevent tumor
initiation and progression [28,29]. Genistein (40,5,7- trihydroxy-
flavone) is abundant in soy products and has been identified as an
inhibitor of protein tyrosine kinases and thus may play a key role
in cell growth and apoptosis [30,31]. It has been reported to have
estrogenic properties and anti-neoplastic activity in multiple tumor
types [32]. It has also been found to have epigenetic effects in the
mouse prostate [33]. In a previous study Hillman et. al. have shown
that the combination of genistein with primary tumor irradiation
acts more effectively as a therapeutic approach, in established
kidney tumors, due to tumor growth being inhibited in both
primary and metastatic sites. In their study genistein alone
demonstrated a tendency to stimulate growth of primary kidney
tumor and increase metastasis [34]. In our study we take a simpler
approach and have shown that A-498 cells treated with genistein
only formed reduced tumors as compared to vehicle controls.
miRNAs regulate gene expression by targeting genes containing
complementary mRNA sequences [35]. Many cellular pathways
are affected by the regulatory function of miRNAs and the most
prominent of these pathways control developmental and onco-
genic processes [36]. miR-21 was one of the first miRNAs detected
in the human genome [37] and has been found to be
overexpressed in a variety of cancer types [38]. There are a few
studies documenting the functional relevance of miR-21 by
showing the cause and effect relationship between miR-21 and
neoplastic transformation. These studies have been done on
glioblastoma [39], breast cancer [40], hepatocellular carcinoma
[41], colorectal cancer [42] and in myeloma cells [43]. A recent
report on the role of miR-21 in renal cancer shows that it
modulates apoptosis through targeting several genes by Zhang et.al
[44]. However to date there is no data which relates clinical
correlation of miR-21 expression with the stage and survival of
Figure 5. In vitro and In vivo effect of genistein on the expression of miR-21. (a) Effect of genistein (25 mM) on the expression of miR-21 in A-
498 cells: miR-21 expression was found to be reduced by ,30% in genistein treated A-498 cells as compared to untreated cells. (b) In vivo effect of
genistein on tumor size in nude mice: Genistein was able to reduce tumor formation significantly (black arrows, right panel).
doi:10.1371/journal.pone.0031060.g005
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role of genistein in inhibiting tumor formation in vivo by decreasing
miR-21 expression in mouse tumors. In conclusion this is the first
report to correlate miR-21 levels with survival and stage of renal
cancer patients and documents the oncogenic role of miR-21
through various cellular pathways.
Materials and Methods
Ethics Statement
Formalin-fixed, paraffin-embedded (FFPE) renal cancer samples
were obtained from the San Francisco Veterans Affairs (VA)
Medical Center. Written informed consent was obtained from all
patients and the study was approved by the UCSF Committee on
Human Research (Approval number: H9058-35751-01). All
animal care was in accordance with the guidelines of the San
Francisco Veterans Affairs Medical Center and the study was
approved by the San Francisco VA IACUC (Protocol number: 08-
003-01).
Cell lines and cell culture
Human renal cancer cell lines A-498, Caki-1, Caki-2, and
normal renal cell line HK-2 were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). The cell
lines were checked by ATCC through DNA (STR) profiling.
Normal renal HK-2 cells were cultured as a monolayer in
Keratinocyte Serum Free Medium (K-SFM) supplemented with
0.05 mg/ml bovine pituitary extract (BPE), 5 ng/ml human
recombinant epidermal growth factor (EGF) (Life Technologies/
Invitrogen, Carlsbad, CA, USA) and 10% fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA, USA), 50 mg/ml peni-
cillin and 50 mg/ml streptomycin (Invitrogen, Carlsbad, CA,
USA). The renal cancer cell line A-498 was cultured as a
monolayer in Eagle’s Minimum Essential Medium, (UCSF Cell
Culture Facility, San Francisco, CA, USA). Caki-1 and Caki-2
were cultured the same way in McCoy’s5A media (UCSF Cell
Culture Facility, San Francisco, CA, USA). All cell lines were
maintained in an incubator with a humidified atmosphere of 95%
air and 5% CO2 at 37uC. Subconfluent A-498cells (60–70%
confluent) were treated with Genistein (25 mM). Genistein (Sigma-
Aldrich Corp., St Louis, MO, USA) was dissolved in DMSO, and
cells treated only with vehicle (DMSO) served as control. Fresh
genistein was administered everyday along with a change of
medium, and the cells incubated for 4 days.
Quantitative real-time PCR
First-strand cDNA was prepared from total RNA (1 mg) using a
reverse transcription system (Promega, Madison, WI, USA). Total
RNA was extracted using an RNeasy mini kit from Qiagen
(Valencia, CA, USA). For real-time polymerase chain reaction
(PCR), complementary DNA was amplified with Inventoried
Gene Assay Products containing two gene-specific primers and
one TaqMan MGB probe (6-FAM dye-labeled) using a TaqMan
Universal Fast PCR Master Mix in a 7500 Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA). Thermal
cycling conditions included 95uC for 20 seconds(s), 40 cycles of
95uC for 3 s and 60uC for 30 s according to the TaqMan Fast
Universal PCR protocol. GAPDH was used as an endogenous
control. For miRNA real-time experiments the cDNA strand was
synthesised using Applied Biosystems Taqman MicroRNA
Reverse Transcription kit, with 200 ng of total extracted miRNA.
RNU48 was used as an endogenous control. For real-time PCR
experiments, where miRNAs were isolated from formalin-fixed
paraffin-embedded (FFPE) renal samples, let7-f was used as an
endogenous control. Total miRNA was extracted from FFPE
samples using a miRNA FFPE kit from Qiagen.
PCR arrays through real-time PCR
To study the expression profile of genes involved in various
cellular pathways, pathway-specific PCR arrays (cell cycle array,
apoptosis array, MAP kinase array, SABioscience) were used
according to the manufacturer’s instructions. Data was analyzed
with the manufacturer’s software.
Micro dissection of renal cancer tissues and RNA
extraction from FFPE human renal tumor samples
Adjacent normal and cancerous renal tissues were obtained
from 39 representative FFPE tissue blocks of radical nephrectomy
specimens from the Pathology Department of the Veterans Affairs
(VA) Medical Center of San Francisco. The blocks were from
kidney cancer patients who were operated on at the VA Medical
Center between 1980–2009. Sections (4 mm) of the blocks were
prepared, H&E stained, and slides were reviewed by a board
certified pathologist to mark the normal and cancer areas.
Subsequently, 12 mm slides were made from the blocks and
microdissection was performed using the marked H&E stained
slides as a template. MicroRNA extraction was done using a
Qiagen FFPE miRNA extraction kit. The levels of miR-21 were
assessed by the Taqman miR assay as described above. Following
PCR, relative miR-21 expression levels in cancerous regions were
normalised to their adjacent normal counterparts.
Cell transfection
A498 and Caki-2 cells were transiently transfected with either
an inhibitor of miRNA-21 or anti-miR negative control #1 (from
Ambion, Austin, TX, USA), using X-tremeGENE siRNA
transfection reagent (Roche Diagnostics Indianapolis, IN, USA)
according to the manufacturer’s protocol. In brief, cells were
seeded in 6 well plates (Nunc, Roskilde, Denmark) 24 h before
transfection and were transiently transfected at a confluency of 40–
50%. Mock transfection, with the transfection reagent, was also
used as a control. The transfection mixture was dissolved in Opti-
MEM serum-free media (UCSF Cell Culture Facility, San
Francisco, CA, USA) and at the time of transfection cells were
seeded in Eagle’s Minimum Essential Medium (UCSF Cell culture
facility), with 10% FBS (Atlanta Biologicals, Lawrenceville, GA,
USA) and no antibiotics. On the following day the media was
changed to Eagle’s Minimum Essential Medium containing both
FBS and 1% antibiotic (penicillin–streptomycin, 1006, UCSF Cell
Culture Facility). Cells were pelleted after 72 h of transfection for
flow cytometry, RNA and protein extraction.
Cell cycle analysis
Cell cycle analysis was performed 72 h after transfection. The
cells were harvested, washed with cold PBS, UCSF Cell Culture
Facility, and resuspended in the nuclear stain 49,6-diamidino-2-
phenylindole (Beckman Coulter, Brea, CA, USA). Stained cells
were immediately analysed with a flow cytometer (Cell Lab
Quanta SC; Beckman Coulter).
Apoptosis assay
For apoptosis, cells at 72 h after transfection were dual stained
with the viability dye 7-amino-actinomycin D and Annexin V-
FITC using an Annexin V-FITC/7-amino-actinomycin D kit
(Beckman Coulter) according to the manufacturer’s protocol.
Stained cells were immediately analysed by flow cytometry (Cell
Lab Quanta SC; Beckman Coulter).
miRNA-21 in Renal Cell Carcinoma
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A cytoselect 24-well cell migration and invasion assay kit (Cell
Biolabs, Inc., San Diego, CA) was used for migration and invasion
assays at 72 hrs after transfection (8 mm, Colorimetric format)
according to the manufacturer’s protocol.
Western analysis
Whole-cell extracts were prepared in radioimmunoprecipitation
assay buffer (RIPA; Thermo Scientific, Rockford, IL, USA;
50 mmol l–1 Tris (pH 8.0), 150 mmol l–1 NaCl, 0.5% deoxy-
cholate, 0.1% SDS and 1.0% NP-40) containing a protease
inhibitor cocktail (Roche, Basel, Switzerland). Protein assays were
performed using a BCA Protein assay kit (Pierce/Thermo
Scientific, Rockford, IL, USA) according to the manufacturer’s
instructions. Total protein (40 mg) was electrophoresed in 12%
SDS–PAGE gels, and Western blotting was carried out using
standard protocols and detected by chemiluminescence. All
antibodies, which included p21(cat. no. 2552), p38 MAPkinase
(cat. no. 9212) and cyclinE2 (cat. no. 4132) were purchased from
Cell Signaling (Danvers, MA, USA), whereas GAPDH (cat. no. sc-
32233) was from Santa Cruz Biotechnology (Santa Cruz, CA).
Genistein treatment of A-498 cells and sub-cutaneous
injection in nude mice
As mentioned above, A-498 cells were treated with 25 mM
genistein for 96 hours. DMSO (vehicle) treated cells served as the
control. After 96 hours the cells were pelleted and ,2 million cells
were injected subcutaneously (100 ml) in the right flank of nude
mice (4- to 5-week old; Charles River Laboratories). Two sets of
mice, with three mice each, were used for this experiment. One set
represented the vehicle (DMSO) controls and the other genistein
treated cells. Tumors from control and genistein treated cells were
excised after 8 weeks when the DMSO treated control mice
developed tumors approximately 800 mm
3 in volume (length-
16 mm, breadth-10 mm). Total RNA was extracted by homog-
enizing the tumors in Qiazol and extracting RNA using the
manufacturer’s protocol (Qiagen). Expression of miR-21 was
measured by real-time PCR.
Statistical analysis
Statistical analysis was performed using StatView version 5.0 for
Windows. Student’s t-test was used to compare the different
groups. p-values of ,0.05 were regarded as statistically significant.
Supporting Information
Figure S1 miR-21 levels in patients having low expression
(,1.2): Low levels of miR-21 in patients with 100% survival.
(TIF)
Figure S2 miR-21 levels in patients having high expression
(.1.2): High levels of miR-21 in patients with 50% survival.
(TIF)
Figure S3 Expression levels of miR-21 after knockdown in A-
498 cells: The miR-21 level was reduced by more than 99% (1.0 to
0.030), as compared to the negative control.
(TIF)
Figure S4 Expression levels of miR-21 after knockdown in Caki-
2 cells: The miR-21 level was reduced by more than 99% (1.0 to
0.011), as compared to the negative control.
(TIF)
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